Korean Circ J.  2022 Aug;52(8):563-575. 10.4070/kcj.2022.0159.

Major Clinical Issues in Hypertrophic Cardiomyopathy

• Lee HJ
• Kim J
• Chang SA
• Kim YJ
• Kim HK
• Lee SC

• KMID: 2532327
• DOI: http://doi.org/10.4070/kcj.2022.0159

Abstract

Hypertrophic cardiomyopathy (HCM) is one of the most common inheritable cardiomyopathies. Contemporary management strategies, including the advent of implantable cardioverter-defibrillators and effective anticoagulation, have substantially improved the clinical course of HCM patients; however, the disease burden of HCM is still high in Korea. Sudden cardiac death (SCD), atrial fibrillation and thromboembolic risk, dynamic left ventricular outflow tract (LVOT) obstruction, and heart failure (HF) progression remain important issues in HCM. SCD in HCM can be effectively prevented with implantable cardioverter-defibrillators. However, appropriate patient selection is important for primary prevention, and the 5-year SCD risk score and the presence of major SCD risk factors should be considered. Anticoagulation should be initiated in all HCM patients with atrial fibrillation regardless of the CHA 2 DS 2 -VASc score, and non-vitamin K antagonist oral anticoagulants are the first option. Symptomatic dynamic LVOT obstruction is first treated medically with negative inotropes, and if symptoms persist, septal reduction therapy is considered. The recently approved myosin inhibitor mavacamten is promising. HF in HCM is usually related to diastolic dysfunction, while about 5% of HCM patients show reduced left ventricular ejection fraction <50%, also referred to as “end-stage” HCM. Myocardial fibrosis plays an important role in the progression to advanced HF in patients with HCM. Patients who do not respond to guideline-directed medical therapy can be considered for heart transplantation. The development of imaging techniques, such as myocardial deformation on echocardiography and late gadolinium enhancement on cardiac magnetic resonance, can provide better risk evaluation and decision-making for management strategies in HCM.

Keyword

Hypertrophic cardiomyopathy; Sudden cardiac death; Atrial fibrillation; Ventricular outflow obstruction; Heart failure

Reference

1. Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958; 20:1–8. PMID: 13499764.

2. Morrow AG, Braunwald E. Functional aortic stenosis; a malformation characterized by resistance to left ventricular outflow without anatomic obstruction. Circulation. 1959; 20:181–189. PMID: 13671704.

3. Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 142:e558–e631. PMID: 33215931.

4. Ho CY, Day SM, Ashley EA, et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation. 2018; 138:1387–1398. PMID: 30297972.

5. Kim KH, Pereira NL. Genetics of cardiomyopathy: clinical and mechanistic implications for heart failure. Korean Circ J. 2021; 51:797–836. PMID: 34327881.

6. Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2015; 65:1249–1254. PMID: 25814232.

7. Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the United States. Am J Cardiol. 2016; 117:1651–1654. PMID: 27006153.

8. Moon I, Lee SY, Kim HK, et al. Trends of the prevalence and incidence of hypertrophic cardiomyopathy in Korea: a nationwide population-based cohort study. PLoS One. 2020; 15:e0227012. PMID: 31929538.

9. Kitaoka H, Doi Y, Casey SA, Hitomi N, Furuno T, Maron BJ. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol. 2003; 92:1183–1186. PMID: 14609593.

10. Kubo T, Kitaoka H, Okawa M, et al. Clinical profiles of hypertrophic cardiomyopathy with apical phenotype--comparison of pure-apical form and distal-dominant form. Circ J. 2009; 73:2330–2336. PMID: 19838003.

11. Kim EK, Lee SC, Hwang JW, et al. Differences in apical and non-apical types of hypertrophic cardiomyopathy: a prospective analysis of clinical, echocardiographic, and cardiac magnetic resonance findings and outcome from 350 patients. Eur Heart J Cardiovasc Imaging. 2016; 17:678–686. PMID: 26245912.

12. Eriksson MJ, Sonnenberg B, Woo A, et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002; 39:638–645. PMID: 11849863.

13. Klarich KW, Attenhofer Jost CH, Binder J, et al. Risk of death in long-term follow-up of patients with apical hypertrophic cardiomyopathy. Am J Cardiol. 2013; 111:1784–1791. PMID: 23540548.

14. Maron BJ, Casey SA, Hauser RG, Aeppli DM. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. J Am Coll Cardiol. 2003; 42:882–888. PMID: 12957437.

15. Rowin EJ, Maron MS, Chan RH, et al. Interaction of adverse disease related pathways in hypertrophic cardiomyopathy. Am J Cardiol. 2017; 120:2256–2264. PMID: 29111210.

16. Kwon S, Kim HK, Kim B, et al. Comparison of mortality and cause of death between adults with and without hypertrophic cardiomyopathy. Sci Rep. 2022; 12:6386. PMID: 35430580.

17. Choi YJ, Kim B, Lee HJ, et al. Emergency department utilization in patients with hypertrophic cardiomyopathy: a nationwide population-based study. Sci Rep. 2022; 12:3534. PMID: 35241727.

18. Maron BJ, Maron MS. Contemporary strategies for risk stratification and prevention of sudden death with the implantable defibrillator in hypertrophic cardiomyopathy. Heart Rhythm. 2016; 13:1155–1165. PMID: 26749314.

19. Mirowski M, Reid PR, Mower MM, et al. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980; 303:322–324. PMID: 6991948.

20. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000; 342:365–373. PMID: 10666426.

21. Schinkel AF, Vriesendorp PA, Sijbrands EJ, Jordaens LJ, ten Cate FJ, Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ Heart Fail. 2012; 5:552–559. PMID: 22821634.

22. Authors/Task Force members. Elliott PM, Anastasakis A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014; 35:2733–2779. PMID: 25173338.

23. O’Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014; 35:2010–2020. PMID: 24126876.

24. Choi YJ, Kim HK, Lee SC, et al. Validation of the hypertrophic cardiomyopathy risk-sudden cardiac death calculator in Asians. Heart. 2019; 105:1892–1897. PMID: 31383719.

25. Gersh BJ, Maron BJ, Bonow RO, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 124:e783–e831. PMID: 22068434.

26. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42:3599–3726. PMID: 34447992.

27. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145:e895–1032. PMID: 35363499.

28. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006; 114:216–225. PMID: 16831987.

29. Rowin EJ, Maron BJ, Carrick RT, et al. Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction. J Am Coll Cardiol. 2020; 75:3033–3043. PMID: 32553256.

30. Marstrand P, Han L, Day SM, et al. Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: insights from the SHaRe Registry. Circulation. 2020; 141:1371–1383. PMID: 32228044.

31. Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: an individualized approach to clinical staging. Circ Heart Fail. 2012; 5:535–546. PMID: 22811549.

32. Park JH. Two-dimensional echocardiographic assessment of myocardial strain: important echocardiographic parameter readily useful in clinical field. Korean Circ J. 2019; 49:908–931. PMID: 31456367.

33. Kobayashi T, Popovic Z, Bhonsale A, et al. Association between septal strain rate and histopathology in symptomatic hypertrophic cardiomyopathy patients undergoing septal myectomy. Am Heart J. 2013; 166:503–511. PMID: 24016500.

34. Urbano-Moral JA, Rowin EJ, Maron MS, Crean A, Pandian NG. Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2014; 7:11–19. PMID: 24275954.

35. Lee HJ, Kim HK, Lee SC, et al. Supplementary role of left ventricular global longitudinal strain for predicting sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2022; 23:1108–1116. PMID: 34542591.

36. Hiemstra YL, Debonnaire P, Bootsma M, et al. Global longitudinal strain and left atrial volume index provide incremental prognostic value in patients with hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2017; 10:e005706. PMID: 28679523.

37. Udelson JE. Evaluating and reducing the risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2019; 139:727–729. PMID: 30715941.

38. Wang J, Zhang Z, Li Y, Xu Y, Wan K, Chen Y. Variable and limited predictive value of the European Society of Cardiology hypertrophic cardiomyopathy sudden-death risk model: a meta-analysis. Can J Cardiol. 2019; 35:1791–1799. PMID: 31474312.

39. Cho JH. Sudden death and ventricular arrhythmias in heart failure with preserved ejection fraction. Korean Circ J. 2022; 52:251–264. PMID: 35388994.

40. Harrigan CJ, Peters DC, Gibson CM, et al. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology. 2011; 258:128–133. PMID: 21045187.

41. Chan RH, Maron BJ, Olivotto I, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation. 2014; 130:484–495. PMID: 25092278.

42. Weng Z, Yao J, Chan RH, et al. Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC Cardiovasc Imaging. 2016; 9:1392–1402. PMID: 27450876.

43. Park YJ, Park SJ, Kim EK, et al. Semi-quantitative versus quantitative assessments of late gadolinium enhancement extent for predicting spontaneous ventricular tachyarrhythmia events in patients with hypertrophic cardiomyopathy. Sci Rep. 2020; 10:2920. PMID: 32076039.

44. Choi HM, Kim KH, Lee JM, et al. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy. Heart. 2015; 101:870–876. PMID: 25897040.

45. Mentias A, Raeisi-Giglou P, Smedira NG, et al. Late gadolinium enhancement in patients with hypertrophic cardiomyopathy and preserved systolic function. J Am Coll Cardiol. 2018; 72:857–870. PMID: 30115224.

46. Guttmann OP, Rahman MS, O’Mahony C, Anastasakis A, Elliott PM. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart. 2014; 100:465–472. PMID: 24014282.

47. Guttmann OP, Pavlou M, O’Mahony C, et al. Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart. 2017; 103:672–678. PMID: 27794017.

48. Debonnaire P, Joyce E, Hiemstra Y, et al. Left atrial size and function in hypertrophic cardiomyopathy patients and risk of new-onset atrial fibrillation. Circ Arrhythm Electrophysiol. 2017; 10:e004052. PMID: 28183843.

49. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation. 2001; 104:2517–2524. PMID: 11714644.

50. Siontis KC, Geske JB, Ong K, Nishimura RA, Ommen SR, Gersh BJ. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc. 2014; 3:e001002. PMID: 24965028.

51. Lee HJ, Kim HK, Kim M, et al. Clinical impact of atrial fibrillation in a nationwide cohort of hypertrophic cardiomyopathy patients. Ann Transl Med. 2020; 8:1386. PMID: 33313131.

52. Rowin EJ, Hausvater A, Link MS, et al. Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2017; 136:2420–2436. PMID: 28916640.

53. Guttmann OP, Pavlou M, O’Mahony C, et al. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA). Eur J Heart Fail. 2015; 17:837–845. PMID: 26183688.

54. Lee HJ, Kim HK, Jung JH, et al. Novel oral anticoagulants for primary stroke prevention in hypertrophic cardiomyopathy patients with atrial fibrillation. Stroke. 2019; 50:2582–2586. PMID: 31340730.

55. Jung H, Yang PS, Jang E, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation with hypertrophic cardiomyopathy: a nationwide cohort study. Chest. 2019; 155:354–363. PMID: 30472021.

56. Providencia R, Elliott P, Patel K, et al. Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart. 2016; 102:1533–1543. PMID: 27234160.

57. Zhao DS, Shen Y, Zhang Q, et al. Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Europace. 2016; 18:508–520. PMID: 26612881.

58. Kim DH, Handschumacher MD, Levine RA, et al. In vivo measurement of mitral leaflet surface area and subvalvular geometry in patients with asymmetrical septal hypertrophy: insights into the mechanism of outflow tract obstruction. Circulation. 2010; 122:1298–1307. PMID: 20837895.

59. Patel P, Dhillon A, Popovic ZB, et al. Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography. Circ Cardiovasc Imaging. 2015; 8:e003132. PMID: 26082555.

60. Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006; 114:2232–2239. PMID: 17088454.

61. Kubo T, Hirota T, Baba Y, et al. Patients’ characteristics and clinical course of hypertrophic cardiomyopathy in a regional Japanese cohort - results from Kochi RYOMA study. Circ J. 2018; 82:824–830. PMID: 29332907.

62. Ho HH, Lee KL, Lau CP, Tse HF. Clinical characteristics of and long-term outcome in Chinese patients with hypertrophic cardiomyopathy. Am J Med. 2004; 116:19–23. PMID: 14706661.

63. Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020; 396:759–769. PMID: 32871100.

64. Spertus JA, Fine JT, Elliott P, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): health status analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021; 397:2467–2475. PMID: 34004177.

65. Saberi S, Cardim N, Yamani M, et al. Mavacamten favorably impacts cardiac structure in obstructive hypertrophic cardiomyopathy: EXPLORER-HCM cardiac magnetic resonance substudy analysis. Circulation. 2021; 143:606–608. PMID: 33190524.

66. Elliott PM. The end of the beginning for drug therapy in obstructive hypertrophic cardiomyopathy with EXPLORER-HCM. Cardiovasc Res. 2020; 116:e175–e178. PMID: 33096564.

67. Ahn HS, Kim HK, Park EA, et al. Coronary flow reserve impairment in apical vs asymmetrical septal hypertrophic cardiomyopathy. Clin Cardiol. 2013; 36:207–216. PMID: 23378014.

68. Kim EK, Lee SC, Chang SA, et al. Prevalence and clinical significance of cardiovascular magnetic resonance adenosine stress-induced myocardial perfusion defect in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2020; 22:30. PMID: 32366254.

69. Dass S, Cochlin LE, Suttie JJ, et al. Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction. Eur Heart J. 2015; 36:1547–1554. PMID: 25990345.

70. Raphael CE, Mitchell F, Kanaganayagam GS, et al. Cardiovascular magnetic resonance predictors of heart failure in hypertrophic cardiomyopathy: the role of myocardial replacement fibrosis and the microcirculation. J Cardiovasc Magn Reson. 2021; 23:26. PMID: 33685501.

71. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 29:277–314. PMID: 27037982.

72. Geske JB, Sorajja P, Nishimura RA, Ommen SR. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation. 2007; 116:2702–2708. PMID: 18025528.

73. Geske JB, Sorajja P, Nishimura RA, Ommen SR. The relationship of left atrial volume and left atrial pressure in patients with hypertrophic cardiomyopathy: an echocardiographic and cardiac catheterization study. J Am Soc Echocardiogr. 2009; 22:961–966. PMID: 19524402.

74. Thomas L, Marwick TH, Popescu BA, Donal E, Badano LP. Left atrial structure and function, and left ventricular diastolic dysfunction: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019; 73:1961–1977. PMID: 31000000.

75. Huynh QL, Kalam K, Iannaccone A, Negishi K, Thomas L, Marwick TH. Functional and anatomic responses of the left atrium to change in estimated left ventricular filling pressure. J Am Soc Echocardiogr. 2015; 28:1428–1433.e1. PMID: 26343250.

76. Singh A, Addetia K, Maffessanti F, Mor-Avi V, Lang RM. LA strain for categorization of LV diastolic dysfunction. JACC Cardiovasc Imaging. 2017; 10:735–743. PMID: 28017389.

77. Morris DA, Belyavskiy E, Aravind-Kumar R, et al. Potential usefulness and clinical relevance of adding left atrial strain to left atrial volume index in the detection of left ventricular diastolic dysfunction. JACC Cardiovasc Imaging. 2018; 11:1405–1415. PMID: 29153567.

78. Smiseth OA, Morris DA, Cardim N, et al. Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2022; 23:e34–e61. PMID: 34729586.

79. Lee HJ, Kim HK, Rhee TM, et al. Left atrial reservoir strain-based left ventricular diastolic function grading and incident heart failure in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2022; 15:e013556. PMID: 35439039.

80. Oh JK, Miranda WR. Left atrial reservoir strain: a savior to diastolic function assessment in hypertrophic cardiomyopathy? Circ Cardiovasc Imaging. 2022; 15:e014148. PMID: 35439040.

81. Pasqualucci D, Fornaro A, Castelli G, et al. Clinical spectrum, therapeutic options, and outcome of advanced heart failure in hypertrophic cardiomyopathy. Circ Heart Fail. 2015; 8:1014–1021. PMID: 26446673.

82. Galati G, Leone O, Pasquale F, et al. Histological and histometric characterization of myocardial fibrosis in end-stage hypertrophic cardiomyopathy: a clinical-pathological study of 30 explanted hearts. Circ Heart Fail. 2016; 9:e003090. PMID: 27618852.

83. Habib M, Adler A, Fardfini K, et al. Progression of myocardial fibrosis in hypertrophic cardiomyopathy: a cardiac magnetic resonance study. JACC Cardiovasc Imaging. 2021; 14:947–958. PMID: 33248971.

84. Zhu Y, Park EA, Lee W, et al. Extent of late gadolinium enhancement at right ventricular insertion points in patients with hypertrophic cardiomyopathy: relation with diastolic dysfunction. Eur Radiol. 2015; 25:1190–1200. PMID: 25597022.

85. Bravo PE, Luo HC, Pozios I, et al. Late gadolinium enhancement confined to the right ventricular insertion points in hypertrophic cardiomyopathy: an intermediate stage phenotype? Eur Heart J Cardiovasc Imaging. 2016; 17:293–300. PMID: 26077330.

86. Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant. 2016; 35:1–23. PMID: 26776864.

87. Melacini P, Basso C, Angelini A, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2010; 31:2111–2123. PMID: 20513729.

88. Anter E, Jessup M, Callans DJ. Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. Circulation. 2009; 119:2516–2525. PMID: 19433768.

89. Lee HJ, Kim HK, Kim BS, et al. Impact of diabetes mellitus on the outcomes of subjects with hypertrophic cardiomyopathy: a nationwide cohort study. Diabetes Res Clin Pract. 2022; 186:109838. PMID: 35314254.

90. Wasserstrum Y, Barriales-Villa R, Fernández-Fernández X, et al. The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy. Eur Heart J. 2019; 40:1671–1677. PMID: 30358878.

91. Kim M, Kim B, Choi YJ, et al. Sex differences in the prognosis of patients with hypertrophic cardiomyopathy. Sci Rep. 2021; 11:4854. PMID: 33649405.

92. Lee HJ, Kim HK, Lee SC, et al. Age-related sex differences in the outcomes of patients with hypertrophic cardiomyopathy. PLoS One. 2022; 17:e0264580. PMID: 35213653.

93. Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. Circulation. 2003; 108:2342–2348. PMID: 14581405.

94. van der Velde N, Huurman R, Yamasaki Y, et al. Frequency and significance of coronary artery disease and myocardial bridging in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2020; 125:1404–1412. PMID: 32111340.